Gilead Sciences, Inc.
http://www.gilead.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gilead Sciences, Inc.
NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
Strides Pushes Back US Expectations
Strides has pushed back US revenue guidance of $225m-$250m by a year to FY23 amid price erosion and substantial competition in the market. Meanwhile, the firm’s CEO says Merck’s molnupiravir and Pfizer’s Paxlovid are not seen impacting COVID-19 vaccine uptake as boosters and immunization for travel will drive continued demand. The Indian company expects to book Sputnik Light sales from Q4.
Gilead Trial Pause Adds To Merck & Co’s HIV Concerns
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.
Consolidation And COVID See Off-Patent Industry Rankings Rewritten
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Arresto Biosciences, Inc.
- Asegua Therapeutics, LLC
- Calistoga Pharmaceuticals, Inc.
- CGI Pharmaceuticals, Inc.
- CV Therapeutics, Inc.
- Cytopia Limited
- EpiTherapeutics
- Eximias Pharmaceutical Corporation
- Immunomedics, Inc.
- Myogen
- MYR GmbH
- Nimbus Apollo, Inc.
- Nexstar Pharmaceuticals
- Oligogen, Inc.
- Pharmasset, Inc.
- Triangle Pharmaceuticals
- YM BioSciences Inc. (YMI)
- Kite Pharma, Inc.
- Kite Pharma EU
- T-Cell Factory B.V. (TCF)
- Cell Design Labs, Inc.
- Asegua Therapeutics